Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Sandborn

Showing results (131-140 of 186) with videos related to

Pageof 19
Sort By:
Alimentary Pharmacology & Therapeutics|July 22, 2014
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitisD Wolf, G D'Haens, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|September 22, 2015
Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trialsV Jairath, R Khanna, G Y Zou, et al.
Gut|July 1, 1996
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administrationE C Van Os, B J Zins, W J Sandborn, et al.
Inflammatory Bowel Diseases|August 24, 1999
Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitisB Louvet, M P Buisine, P Desreumaux, et al.
Alimentary Pharmacology & Therapeutics|August 23, 2014
Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 studyW J Sandborn, S D Lee, C Randall, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2009
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trialsG R Lichtenstein, R H Diamond, C L Wagner, et al.
Current Medical Research and Opinion|February 27, 2013
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's diseaseW J Sandborn, J-F Colombel, G D'Haens, et al.
Alimentary Pharmacology & Therapeutics|August 13, 2015
Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's diseaseS Singh, N S Ding, K L Mathis, et al.
Gut|May 2, 2006
Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive proteinJ F Colombel, C A Solem, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|March 3, 2015
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysisJ-F Colombel, W Reinisch, G J Mantzaris, et al.
Pageof 19

Showing results (131-140 of 186) with videos related to

Sort By:
Pageof 19
Alimentary Pharmacology & Therapeutics|July 22, 2014
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitisD Wolf, G D'Haens, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|September 22, 2015
Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trialsV Jairath, R Khanna, G Y Zou, et al.
Gut|July 1, 1996
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administrationE C Van Os, B J Zins, W J Sandborn, et al.
Inflammatory Bowel Diseases|August 24, 1999
Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitisB Louvet, M P Buisine, P Desreumaux, et al.
Alimentary Pharmacology & Therapeutics|August 23, 2014
Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 studyW J Sandborn, S D Lee, C Randall, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2009
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trialsG R Lichtenstein, R H Diamond, C L Wagner, et al.
Current Medical Research and Opinion|February 27, 2013
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's diseaseW J Sandborn, J-F Colombel, G D'Haens, et al.
Alimentary Pharmacology & Therapeutics|August 13, 2015
Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's diseaseS Singh, N S Ding, K L Mathis, et al.
Gut|May 2, 2006
Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive proteinJ F Colombel, C A Solem, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|March 3, 2015
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysisJ-F Colombel, W Reinisch, G J Mantzaris, et al.
Pageof 19